Market access has become a key focus for governments across the globe in 2018 – though as ever a balance between what is good for the industry and what is good for countries and their healt
US authorities looking into price fixing in the generics industry are now investigating 16 companies and the price of at least 300 drugs, according to a press report.
Boehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira near-copy on the US market as soon as possible.
The UK government has reached a new five-year medicines pricing deal with the pharma industry to replace the almost 60-year-old Pharmaceutical Price Regulation Scheme (PPRS).